Pharmasia Ltd Stock Price Today (NSE: PHRMASI)
Fundamental Score
Pharmasia Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Pharmasia Ltd share price today is ₹82.75, down 2.62% on NSE/BSE as of 7 August 2026. Pharmasia Ltd (PHRMASI) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹57.69 (Cr). The 52-week high for PHRMASI share price is ₹131.75 and the 52-week low is ₹26.00. At a P/E ratio of 29.28x, PHRMASI is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 12.78% and a debt-to-equity ratio of 0.05.
Pharmasia Ltd Share Price Chart — NSE/BSE Historical Performance
Pharmasia Ltd share price chart: -7.73% return over the past month. 52-week high ₹131.75, 52-week low ₹26.00.
Pharmasia Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹84.99 | ₹84.99 | ₹82.74 | ₹82.75 | 177.00 (Cr) | |
| ₹81.07 | ₹85.00 | ₹81.07 | ₹84.98 | 415.00 (Cr) | |
| ₹84.00 | ₹84.00 | ₹82.89 | ₹83.24 | 146.00 (Cr) | |
| ₹87.70 | ₹87.70 | ₹87.25 | ₹87.25 | 402.00 (Cr) | |
| ₹87.70 | ₹87.70 | ₹86.00 | ₹87.70 | 193.00 (Cr) | |
| ₹85.00 | ₹89.00 | ₹80.75 | ₹88.65 | 412.00 (Cr) | |
| ₹92.00 | ₹92.00 | ₹84.80 | ₹85.00 | 186.00 (Cr) | |
| ₹97.50 | ₹97.65 | ₹89.25 | ₹89.25 | 1.50K (Cr) | |
| ₹93.84 | ₹93.90 | ₹93.00 | ₹93.00 | 690.00 (Cr) | |
| ₹90.00 | ₹93.87 | ₹85.00 | ₹93.87 | 6.00 (Cr) |
Pharmasia Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹87.70 | ₹87.70 | ₹81.07 | ₹82.75 | -5.64% | |
| ₹99.95 | ₹103.67 | ₹80.75 | ₹88.65 | -11.31% | |
| ₹77.00 | ₹111.13 | ₹75.59 | ₹100.00 | +29.87% | |
| ₹98.16 | ₹103.06 | ₹77.20 | ₹77.45 | -21.10% | |
| ₹75.20 | ₹114.00 | ₹69.00 | ₹98.16 | +30.53% | |
| ₹86.59 | ₹89.94 | ₹74.83 | ₹75.20 | -13.15% | |
| ₹99.00 | ₹123.97 | ₹86.59 | ₹86.59 | -12.54% | |
| ₹114.95 | ₹131.75 | ₹92.80 | ₹99.00 | -13.88% | |
| ₹65.75 | ₹112.74 | ₹65.75 | ₹112.74 | +71.47% | |
| ₹30.32 | ₹62.62 | ₹30.32 | ₹62.62 | +106.53% | |
| ₹35.39 | ₹39.59 | ₹30.01 | ₹33.67 | -4.86% | |
| ₹34.20 | ₹42.02 | ₹30.88 | ₹35.22 | +2.98% |
AI Research Briefing
Powered by Gemini · 2026-04-08
Expensive micro-cap turnaround story with a history of poor profitability and significant liquidity risk.
WHAT'S HAPPENING NOW
No major catalysts found for Pharmasia Ltd after live search. The latest news revolves around the broader Indian pharmaceutical sector, with mentions of FDA approvals for Aurobindo and Alembic, and discussions around pay hikes and tariff policies.
CORE STORY
Pharmasia is a micro-cap play on oral contraceptive pills and iron tablets in India. The market is likely pricing in a turnaround story given the recent YoY profit and sales growth, but the company's historical performance raises concerns.
- Recent surge in profitability (YoY)
- Micro-cap momentum
- Positive sector sentiment
- Sustained profitability in coming quarters
- New order wins
- Acquisition by a larger player
- Micro-cap liquidity risk
- Negative ROE/ROCE
- Expensive valuation (P/E 57.57x vs Industry P/E 31.77x)
Promoter holding is high at 73.51%, but no recent change. FII/DII holdings are negligible.
Mixed. Positive sentiment for the Indian pharmaceutical sector, but US pharma tariff policies create uncertainty.
Poor. Free Cash Flow 5Y: ₹0.6 Cr
If Pharmasia can sustain its recent growth and improve profitability, it could be a compelling investment. However, the risks are significant, and investors should proceed with caution.
Primary Thesis Risk
Illiquidity and a history of unprofitability make this a very risky bet.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Pharmasia Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Pharmasia Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of PHRMASI across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Excellent ROCE Performance (16.39%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Revenue Growth (42.36%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (23.85% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (44.75% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (44.75% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.05)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (11.91x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (73.51%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Margin Pressure Concerns (-2.90%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Profit Decline Concern (-32.08%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Limited Institutional Interest (FII+DII: 0.05%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Pharmasia Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Pharmasia Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Pharmasia LtdPharmasia Ltd...Selected✓ PHRMASI • 523620 | 60/100 | ₹82.75₹83 | ₹57.69₹57.69 | 29.28Average 29.3 Average | 12.78%Average 12.78% Average | 16.39%Good 16.39% Good | 0.05Excellent 0.1 Excellent | 44.75%Excellent 44.75% Excellent | 23.85%Excellent 23.85% Excellent | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Pharmasia Ltd Quarterly Performance
Latest quarterly metrics for PHRMASI — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
42.36%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-32.08%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
23.85%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
44.75%
Compounded annual net profit growth over 5 years
Pharmasia Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for PHRMASI — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Pharmasia Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Pharmasia Ltd (PHRMASI) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Pharmasia Ltd
About PHRMASI (Pharmasia Ltd)
Pharmasia Ltd is a dynamic pharmaceutical entity focused on the development, manufacture, and commercialization of specialized therapeutic solutions. With a commitment to advancing... healthcare outcomes, Pharmasia dedicates its resources to addressing unmet medical needs within niche therapeutic areas. The company's expertise lies in formulating innovative medications and delivery systems designed to improve patient compliance and enhance therapeutic efficacy. Pharmasia leverages cutting-edge research and development strategies, partnering with leading scientific institutions and employing a team of highly skilled professionals to drive its product pipeline forward. The company is dedicated to rigorous quality control throughout its manufacturing processes, adhering to the highest industry standards and regulatory guidelines to ensure the safety and reliability of its pharmaceutical offerings. Pharmasia's product portfolio showcases a strategic concentration on specialized formulations and targeted therapies. This includes a range of advanced medications for managing chronic conditions. Pharmasia's commitment extends beyond simply producing drugs; it focuses on creating comprehensive solutions for patients, which includes disease awareness programs and patient support services. The company's sales and marketing teams are highly trained to engage with healthcare professionals, providing accurate information and education about Pharmasia's products, ensuring proper usage and optimal patient outcomes. The company strives to cultivate strong relationships with key opinion leaders and medical societies to stay at the forefront of medical advancements and refine its therapeutic strategies. Pharmasia operates with a strong ethical framework, emphasizing integrity and transparency in all aspects of its business. The company is committed to sustainable practices, minimizing its environmental impact and contributing positively to the communities where it operates. Pharmasia recognizes its responsibility to improve global health and actively participates in initiatives to enhance access to essential medicines in underserved populations. By prioritizing innovation, quality, and social responsibility, Pharmasia is striving to be a trusted partner in healthcare, delivering life-changing therapies and contributing to a healthier future for all. The company has plans for an expansion in research and development facilities to further its impact on the growing global pharmaceutical industry.
Company Details
Key Leadership
Latest News
PHRMASI Share Price: Frequently Asked Questions
What is the current share price of Pharmasia Ltd?
Pharmasia Ltd (PHRMASI) trades at ₹82.75 on NSE and BSE. Market cap ₹57.69 (Cr). Educational data only.
What is the P/E ratio of Pharmasia Ltd?
Pharmasia Ltd has a P/E of 29.28x vs industry average 34.89x.
What is the Bull Run score for Pharmasia Ltd?
Pharmasia Ltd has a Bull Run score of 60/100 based on 25+ financial parameters.
Does Pharmasia Ltd pay dividends?
Pharmasia Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Pharmasia Ltd?
Pharmasia Ltd has ROE of 12.78%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Pharmasia Ltd?
Pharmasia Ltd has debt-to-equity of 0.05.
Is Pharmasia Ltd a good investment?
Bull Run gives Pharmasia Ltd a score of 60/100. This is not investment advice — consult a SEBI-registered advisor.